Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clearmind Medicine Inc CMND

Healthcare
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or... see more

Recent & Breaking News (NDAQ:CMND)

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

GlobeNewswire May 7, 2024

Clearmind Applies to Cease Being a Reporting Issuer in Canada

GlobeNewswire April 30, 2024

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

GlobeNewswire April 17, 2024

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

GlobeNewswire April 10, 2024

Clearmind Medicine CEO Issues Letter to Shareholders

GlobeNewswire April 9, 2024

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

GlobeNewswire March 27, 2024

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

GlobeNewswire March 19, 2024

CSE Bulletin: Delist - Clearmind Medicine Inc. (CMND)

Newsfile March 13, 2024

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

GlobeNewswire March 13, 2024

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

GlobeNewswire March 13, 2024

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

GlobeNewswire February 27, 2024

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

GlobeNewswire February 27, 2024

Clearmind Medicine to begin alcohol use disorder clinical trial

Jocelyn Aspa February 23, 2024

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

GlobeNewswire February 23, 2024

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

GlobeNewswire February 20, 2024

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

GlobeNewswire February 20, 2024

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

GlobeNewswire February 5, 2024

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

GlobeNewswire February 1, 2024

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

Accesswire January 16, 2024

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

GlobeNewswire January 16, 2024